F Oberling

3.9k total citations · 1 hit paper
111 papers, 2.9k citations indexed

About

F Oberling is a scholar working on Oncology, Pathology and Forensic Medicine and Immunology. According to data from OpenAlex, F Oberling has authored 111 papers receiving a total of 2.9k indexed citations (citations by other indexed papers that have themselves been cited), including 24 papers in Oncology, 23 papers in Pathology and Forensic Medicine and 22 papers in Immunology. Recurrent topics in F Oberling's work include Lymphoma Diagnosis and Treatment (13 papers), Chronic Lymphocytic Leukemia Research (10 papers) and Immune Cell Function and Interaction (10 papers). F Oberling is often cited by papers focused on Lymphoma Diagnosis and Treatment (13 papers), Chronic Lymphocytic Leukemia Research (10 papers) and Immune Cell Function and Interaction (10 papers). F Oberling collaborates with scholars based in France, Switzerland and United States. F Oberling's co-authors include J L Binet, Guillaume Dighiero, G Potron, H Piguet, F Grémy, Gil Tchernia, Ariane Auquier, J. Goasguen, Pierre Boivin and G Vaugier and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Annals of Internal Medicine.

In The Last Decade

F Oberling

105 papers receiving 2.7k citations

Hit Papers

A new prognostic classification of chronic lymphocytic le... 1981 2026 1996 2011 1981 400 800 1.2k

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
F Oberling France 21 1.4k 1.1k 973 739 522 111 2.9k
John C. Cawley United Kingdom 36 2.1k 1.5× 1.1k 1.0× 1.7k 1.8× 1.2k 1.6× 702 1.3× 135 3.8k
Antonio Pezzutto Germany 35 669 0.5× 763 0.7× 2.0k 2.0× 871 1.2× 1.2k 2.4× 158 4.0k
Eckhart Weidmann Germany 38 1.3k 0.9× 2.1k 1.9× 1.3k 1.3× 1.4k 1.9× 2.0k 3.8× 111 5.0k
TM Grogan United States 26 711 0.5× 1.4k 1.3× 603 0.6× 1.0k 1.4× 2.0k 3.8× 58 3.6k
Harald Stein Germany 33 672 0.5× 1.9k 1.7× 1.1k 1.2× 941 1.3× 1.5k 2.8× 53 4.0k
Maurizio Bendandi Italy 41 884 0.6× 2.4k 2.1× 1.9k 2.0× 1.0k 1.4× 1.9k 3.6× 112 4.7k
Marco Gobbi Italy 33 896 0.6× 644 0.6× 969 1.0× 1.0k 1.4× 1.3k 2.5× 171 3.9k
Dianne Sako United States 21 471 0.3× 508 0.5× 816 0.8× 1.4k 1.8× 457 0.9× 32 3.2k
Javier Briones Spain 35 957 0.7× 1.3k 1.2× 1.7k 1.7× 831 1.1× 1.9k 3.6× 161 4.5k
Shigeo Horiike Japan 31 933 0.7× 869 0.8× 550 0.6× 1.6k 2.2× 935 1.8× 165 4.1k

Countries citing papers authored by F Oberling

Since Specialization
Citations

This map shows the geographic impact of F Oberling's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by F Oberling with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites F Oberling more than expected).

Fields of papers citing papers by F Oberling

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by F Oberling. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by F Oberling. The network helps show where F Oberling may publish in the future.

Co-authorship network of co-authors of F Oberling

This figure shows the co-authorship network connecting the top 25 collaborators of F Oberling. A scholar is included among the top collaborators of F Oberling based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with F Oberling. F Oberling is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Guriec, Nathalie, B Gairard, A Wilk, et al.. (1996). CD44 exon 6 expression as a possible early prognostic factor in primary node negative breast carcinoma. Clinical & Experimental Metastasis. 14(5). 434–439. 18 indexed citations
2.
Feugeas, Olivier, Nathalie Guriec, A Babin-Boilletot, et al.. (1996). Loss of heterozygosity of the RB gene is a poor prognostic factor in patients with osteosarcoma.. Journal of Clinical Oncology. 14(2). 467–472. 141 indexed citations
3.
Kurtz, Jean‐Emmanuel, Emmanuel Andrès, F. Maloisel, et al.. (1995). Intra-abdominal localization of acute leukaemia: report of six cases.. PubMed. 37(5). 273–6. 2 indexed citations
4.
Guastalla, Jean‐Paul, C. Lhommé, J Dauplat, et al.. (1994). Taxol (paclitaxel) safety in patients with platinum pretreated ovarian carcinoma: an interim analysis of a phase II multicenter study.. PubMed. 5 Suppl 6. S33–8. 11 indexed citations
5.
Klein, Théo, Gerhard Jung, P. Dufour, et al.. (1993). Cancer du sein après maladie de Hodgkin. Analyse de 6 observations.. La Presse Médicale. 22(38). 1928–1929.
6.
Dufour, P., et al.. (1993). Sodium ditiocarb as adjuvant immunotherapy for high risk breast cancer: A randomized study. Biotherapy. 6(1). 9–12. 70 indexed citations
7.
Vincent, Florence, Alice Eischen, Henri de la Salle, et al.. (1991). Synthesis of Complement Components C2 and C4 by Human Monocyte-Derived Macrophages during in vitro Differentiation in Serum-Free Culture Conditions. Pathobiology. 59(3). 136–139. 2 indexed citations
8.
Maraninchi, D, Patrice Viens, Michel Legros, et al.. (1990). Hautes doses d'alkylants et autogreffe de moelle dans les cancers de l'ovaire à mauvais pronostic : une analyse rétrospective de 40 patientes traitées en France. Bulletin du Cancer. 77(2). 149–157.
9.
Jacqmin, Didier, et al.. (1987). Metastatic Renal Cell Carcinoma. Interferon Alpha 2 and Vinblastine Combined Therapy. Results of a Series of 21 Patients. The Journal of Urology. 137(6). 1 indexed citations
10.
Dufour, P, et al.. (1985). Choriocarcinome médiastinal au cours de l'évolution d'une leucose aiguë myeloblastique.. La Presse Médicale. 14(17). 979–979. 1 indexed citations
11.
Lang, Jean-Marie, et al.. (1984). High-dose intravenous IgG for chronic idiopathic thrombocytopenic purpura in adults. Annals of Hematology. 49(2). 95–99. 12 indexed citations
12.
Lang, Jean-Marie, Matthew R. Eber, G Méthlin, & F Oberling. (1982). Serum Ferritin During the Course of Chronic Myeloid Leukemia. Increase of Serum Ferritin as a Marker of Dyserythropoiesis. Acta Haematologica. 67(3). 145–149. 4 indexed citations
13.
Binet, J L, Ariane Auquier, Guillaume Dighiero, et al.. (1981). A new prognostic classification of chronic lymphocytic leukemia derived from a multivariate survival analysis. Cancer. 48(1). 198–206. 1282 indexed citations breakdown →
14.
Basset, Paul, Jean‐Pierre Bergerat, Jean-Marie Lang, F Oberling, & Benjamin Gillet. (1981). Hemolytic Anemia and Sulfhemoglobinemia Due to Phenacetin Abuse: A Case with Multivisceral Adverse Effects. Clinical toxicology. 18(4). 493–499. 7 indexed citations
15.
Oberling, F, et al.. (1978). Maladie de Hodgkin. Déficit lymphocytaire thymo-dépendant chez des patients en rémission complète.. Pathologie Biologie. 26. 2 indexed citations
16.
Oberling, F, et al.. (1977). Normal active rosette-forming-cells in untreated patients with Hodgkin's disease.. PubMed. 27(9-10). 322–4. 4 indexed citations
17.
Hauptmann, G., et al.. (1976). Acquired C�1-inhibitor deficiencies in lymphoproliferative diseases with serum immunoglobulin abnormalities. Annals of Hematology. 32(3). 195–206. 40 indexed citations
18.
Oberling, F, et al.. (1974). Lymphocyte reactivity to phytohaemagglutinin and allogeneic lymphocytes in 32 untreated patients with Hodgkin's disease.. PubMed. 21(9). 372–7. 6 indexed citations
19.
Oberling, F, Yosefa Bar Dayan, & Rebecca Waitz. (1973). [Use of stains in routine histopathology of semi-fine slices of "araldite" embedded bone marrow].. PubMed. 13(3). 429–31. 1 indexed citations
20.
Oberling, F, et al.. (1969). [Treatment by immunosuppressive agents of hemorrhagic and purulent rectocolitis. Possible role of lymphocytes].. PubMed. 77(56). 2141–2. 7 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026